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	 In	the	present	study,	synthesis	and	antimicrobial	activity	of	2,5‐disubstituted	1,3,4‐thiadiazole
derivatives	 5a‐f	 are	 described.	 The	 structures	 of	 the	 newly	 synthesized	 compounds	 were
confirmed	 by	 FT‐IR,	 1H	 NMR,	 13C	 NMR,	 mass	 and	 elemental	 analysis.	 All	 compounds	 were
screened	 for	 antitubercular	 and	 antimicrobial	 activity.	 Molecular	 modeling	 studies	 were
performed	 to	 dock	 compounds	 into	 the	 ecKAS	 III	 binding	 site,	 which	 suggested	 probable
inhibition	 mechanism.	 The	 results	 revealed	 that	 most	 of	 the	 compounds	 showed	 high	 to
moderate	biological	activity	against	tested	microorganisms.	
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1.	Introduction	
	
Tuberculosis	(TB)	is	the	leading	infectious	cause	of	death	in	
the	 world	 today,	 with	 approximately	 three	 million	 patients	
deceasing	 every	 year	 [1].	 Nearly	 one‐third	 of	 the	 world’s	
population	is	infected	with	Mycobacterium	tuberculosis	and	the	
World	 Health	 Organization	 (WHO)	 estimates	 that	 about	 30	
million	people	will	be	infected	within	the	next	20	years.	During	
recent	 years,	 M.	 tuberculosis	 and	 microorganisms	 increased	
resistance	 against	 drugs	 [2].	 The	 situation	 is	 becoming	
alarming	 with	 the	 recent	 emergence	 of	 multi‐drug	 resistant	
(MDR)	 strains	 and	 its	 synergy	 with	 global	 Human	
Immunodeficiency	Virus	(HIV)	[3,4].	
During	recent	years,	 there	has	been	 intense	 investigations	
on	 thiadiazole	 i.e	 2,5‐disubstituted	 ‐1,3,4‐thiadiazole	
compounds,	many	of	which,	 are	 known	 to	possess	 interesting	
biological	 properties	 such	 as	 antimicrobial	 [5],	 anti‐
inflammatory	[6],	antifungal	[7],	anticonvulsant	[8],	anti‐tumor	
[9]	 activities.	 Some	 members	 of	 the	 2,5‐disubstituted	 ‐1,3,4‐
thiadiazole	 family	 displayed	 good	 activity	 against	 M.	
tuberculosis	H37Rv	strain	[10].	
Type	 II	 fatty	 acid	 synthesis	 (FAS	 II)	 pathway	 has	 been	
recently	 reported	 as	 an	 attractive	 targeting	 for	 their	 efficacy	
against	 infections	 caused	 by	 mutiresistant	 Gram‐positive	
bacteria	 [11].	 There	 are	 plenty	 of	 fatty	 acids	 available	 to	 the	
bacteria	inside	of	the	host	[12].	However,	FAS	II	 it’s	proven	to	
be	 a	 good	 target	 for	Gram‐negative	 bacteria.	Notably,	 KAS	 III,	
regulates	 the	 fatty	 acid	 biosynthesis	 rate	 via	 an	 initiation	
pathway	 and	 its	 substrate	 specificity	 is	 a	 key	 factor	 in	
membrane	fatty	acid	composition	and	this	protein	represents	a	
promising	target	for	the	antimicrobial	drugs	design	[13].	
Inspired	from	these	observations,	we	planned	to	synthesize	
some	 novel	 1,3,4‐thiadiazole	 derivatives	 (Scheme	 1)	 and	 get	
them	 evaluated	 for	 their	 antitubercular	 and	 antimicrobial	
activity.		
	
2.	Experimental	
	
2.1.	Instrumentation	
	
All	 chemicals	 and	 reagents	 used	 in	 current	 study	were	 of	
analytical	 grade.	 The	 reactions	 were	monitored	 by	 thin	 layer	
chromatography	 (TLC)	 on	 Merck	 pre‐coated	 silica	 GF254	
plates.	 Melting	 points	 (uncorrected)	 were	 determined	 on	 a	
XT4MP	apparatus	(Nanjing	University,	Nanjing,	China).	The	FT‐
IR	 spectra	 were	 recorded	 on	 Thermo	 Nicolet	 IR200	 FT‐IR	
Spectrometer	(Madison	WI,	USA)	by	using	KBr	pellets.	1H	NMR	
spectra	 were	 collected	 on	 a	 Bruker	 DPX400	 spectrometer	 at	
room	 temperature	 with	 TMS	 and	 solvent	 signals	 allotted	 as	
internal	standards.	Chemical	shifts	are	reported	in	ppm	(δ).	13C	
NMR	 spectra	were	 recorded	 (in	 CDCl3/DMSO‐d6)	 on	 a	 Bruker	
DPX400	 spectrometer	 at	 100	 MHz.	 ESI	 mass	 spectra	 were	
obtained	 on	 a	 Mariner	 system	 5304	 mass	 spectrometer.	
Elemental	 analyses	 were	 performed	 on	 a	 CHN‐O‐Rapid	
instrument.	
	
2.2.	Synthesis	
	
2.2.1.	Synthesis	of	2‐(2,4,5‐trisusbtituted	phenylamino)	
acetic	acid	(1)	
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Reagents	used:	i)	Ethanol,	5	h,	125	oC;	ii)	Conc.	sulphuric	acid,	dry	ethanol,	8	h,	90	oC;	iii)	Hydrazine	hydrate,	ethanol,	8	h,	85	oC;		
iv)	Carbon	disulphide,	conc.	sulphuric	acid,	2	h,	85	oC;	v)	p‐substituted	phenacyl	bromide,	1	h,	80	oC.	
	
Scheme	1
	
	
Equimolar	 quantities	 of	 substituted	 aniline	 (0.1	 N),	
chloroacetic	acid	and	sodium	acetate	trihydrate	were	added	in	
presence	of	ethanol	(50	mL)	and	were	refluxed	in	an	oil	bath	at	
125	 oC	 for	5	h.	The	 reaction	mixture	was	poured	 into	 ice‐cold	
water	 (200	 mL),	 the	 precipitated	 solid	 was	 filtered,	 washed	
with	cold	water,	dried	and	recrystallized	using	ethanol.		
2‐(2,4,5‐trichlorophenylamino)acetic	acid	 (1a):	 Yield:	 78%.	
M.p.:	123‐124	oC.	 IR	(KBr,	ν,	cm‐1):	3375	(NH	str.),	3115	(OH),	
2953	(CH2),	1680	(C=O).	1H	NMR	(400	MHz,	DMSO‐d6,	δ,	ppm):	
11.0	(s,	1H,	OH),	7.77	(s,	1H,	Ar‐H),	7.54	(s,	1H,	Ar‐H),	4.08	(s,	
1H,	‐NH),	4.08	(s,	1H,	D2O	Exchange	exp.),	2.82(s,	2H,	CH2).		
2‐(2,4,5‐trifluorophenylamino)acetic	 acid	 (1b):	 Yield:	 66%.	
M.p.:	142‐144	oC.	 IR	(KBr,	ν,	cm‐1):	3415	(NH	str.),	3010	(OH),	
2874	(CH2),	1687	(C=O).	1H	NMR	(400	MHz,	DMSO‐d6,	δ,	ppm):	
11.3	(s,	1H,	OH),	7.65	(s,	1H,	Ar‐H),	7.44	(s,	1H,	Ar‐H),	4.01	(s,	
1H,	‐NH),	4.01	(s,	1H,	D2O	Exchange	exp.),	2.99(s,	2H,	CH2).	
	
2.2.2.	Synthesis	of	ethyl‐2‐(2,4,5‐trisubstitutedphenylamino)	
acetate	(2)	
	
One	gram	of	synthesized	compounds	were	dissolved	in	10‐
15	 mL	 of	 ethanol,	 few	 drops	 of	 conc.	 sulphuric	 acid	 were	
poured	along	the	sides	of	the	container	and	refluxed	for	8‐12	h.	
Simultaneous	in	between	TLC	of	the	sample	were	taken.	i.e.	for	
every	one	hour.	TLC	solvent	ratio	is	ethanol:chloroform	(7:3).		
Ethyl‐2‐(2,4,5‐trichlorophenylamino)acetate	 (2a):	 Yield:	
75%.	M.p.:	 103‐104	 oC.	 IR	 (KBr,	 ν,	 cm‐1):	 3475	 (NH	str.),	 2933	
(CH2),	1722	(C=O).	1H	NMR	(400	MHz,	DMSO‐d6,	δ,	ppm):	7.70	
(s,	1H,	Ar‐H),	7.61	(s,	1H,	Ar‐H),	3.99	(s,	1H,	‐NH),	3.73	(s,	2H,	
CH2),	2.95	(s,	2H,	CH2),	1.15	(s,	3H,	CH3).	
Ethyl‐2‐(2,4,5‐trifluorophenylamino)acetate	 (2b):	 Yield:	
61%.	M.p.:	 137‐139	 oC.	 IR	 (KBr,	 ν,	 cm‐1):	 3401	 (NH	str.),	 2988	
(CH2),	1698	(C=O).	1H	NMR	(400	MHz,	DMSO‐d6,	δ,	ppm):	7.89	
(s,	 1H,	Ar‐H),	7.70(s,	 1H,	Ar‐H),	4.02	 (s,	1H,	 ‐NH),	3.81	 (s,	 2H,	
CH2),	2.85	(s,	2H,	CH2),	1.34	(s,	3H,	CH3).		
	
	
	
2.2.3.	Synthesis	of	2‐(substituted	phenylamino)aceto	
hydrazide	(3)	
	
To	the	prepared	solution	of	an	ester	in	absolute	ethanol	(50	
mL)	 were	 added	 with	 hydrazine	 hydrate	 99%	 in	 equimolar	
quantity.	The	resulting	mixture	were	refluxed	on	a	steam	bath	
for	 8	 h,	 the	 excess	 ethanol	 were	 removed	 under	 reduced	
pressure.	The	resulting	residue	was	poured	into	ice	cold	water	
(200	 mL).	 The	 solid	 hydrazide	 thus	 obtained	 were	
recrystallized	using	ethanol.		
2‐(2,4,5‐trichlorophenylamino)acetohydrazide	 (3a):	 Yield:	
70%.	M.p.:	110‐112	oC.	IR	(KBr,	ν,	cm‐1):	3450	(NH2),	3265	(NH	
str.),	 	2953	(CH2),	1680	(C=O).	1H	NMR	(400	MHz,	DMSO‐d6,	δ,	
ppm):	 8.22	 (s,	 1H,	 NH2),	 7.98	 (s,	 1H,	 NH),	 7.70	 (s,	 1H,	 Ar‐H),	
7.54	(s,	1H,	Ar‐H),	4.08	(s,	1H,	NH),	2.98	(s,	2H,	CH2).	
2‐(2,4,5‐triFluorophenylamino)acetohydrazide	 (3b):	 Yield:	
58%.	M.p.:	140‐142	oC.	IR	(KBr,	ν,	cm‐1):	3398	(NH2),	3235	(NH	
str.),	2935	(CH2),	1678	(C=O).	 1H	NMR	(400	MHz,	DMSO‐d6,	δ,	
ppm):	 8.20	 (s,	 1H,	 NH2),	 7.76	 (s,	 1H,	 NH),	 7.70	 (s,	 1H,	 Ar‐H),	
7.45	(s,	1H,	Ar‐H),	4.01	(s,	1H,	NH),	2.89	(s,	2H,	CH2).	
	
2.2.4.	General	procedure:	Synthesis	of	5‐((2,4,5‐
trisubstitutedphenylamino)methyl)‐1,3,4‐thiadiazole‐2‐
thiol	(4)	
	
To	 the	 obtained	 2‐(2,4,5‐trisubstituted	 phenylamino)	
acetohydrazide,	 add	 equimolar	 quantity	 of	 carbon	 disulphide	
and	 few	 drops	 of	 conc.	 sulphuric	 acid	 in	 presence	 of	 15	 mL	
ethanol	 and	 refluxed	 for	 2	 h,	 after	 reflux	 cooled	 to	 room	
temperature,	 which	 is	 then	 poured	 into	 crushed	 ice	 and	
neutralized	 with	 dilute	 acetic	 acid.	 	 The	 resulting	 solid	 was	
filtered,	washed	with	cold	water,	dried	and	recrystallized	using	
ethanol.		
5‐((2,4,5‐trichlorophenylamino)methyl)‐1,3,4‐thiadiazole‐2‐
thiol	(4a):	Yield:	68%.	M.p.:	125‐126	oC.	IR	(KBr,	ν,	cm‐1):	3377	
(NH	str.),	3117	(CH2),	784	(Cl	str.).	1H	NMR	(400	MHz,	DMSO‐d6,	
δ,	ppm):	12.87	(s,	1H,	‐SH),	7.86	(s,	1H,	Ar‐H),	7.52	(s,	1H,	Ar‐H),	
4.01	(s,	1H,	NH),	2.88	(s,	2H,	CH2).		
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5‐((2,4,5‐trifluorophenylamino)methyl)‐1,3,4‐thiadiazole‐2‐
thiol	(4b):	Yield:	57%.	M.p.:	191‐193	oC.	IR	(KBr,	ν,	cm‐1):	3437	
(NH	str.),	3271	(CH2),	760	(Cl	str.).	1H	NMR	(400	MHz,	DMSO‐d6,	
δ,	ppm):	12.78	(s,	1H,	‐SH),	7.87	(s,	1H,	Ar‐H),	7.67	(s,	1H,	Ar‐H),	
4.07	(s,	1H,	NH),	2.65	(s,	2H,	CH2).		
	
2.2.5.	Preparation	of	derivatives	of	1‐(2,4,5‐trisubstituted	
phenyl)‐2‐(5‐((substitutedphenylamino)methyl)‐1,3,4‐
thiadiazol‐2‐ylthio)ethanone	(5a‐f)	
	
These	 obtained	 5‐((2,4,5‐trisubstitutedphenylamino)	
methyl)‐1,3,4‐thiadiazole‐2‐thiol	 compounds	 (0.005	 mole)	
were	treated	with	equimolar	quantity	of	p‐substituted	phenacyl	
bromide	 (0.005	 mole)	 in	 the	 presence	 of	 ethanol	 (50	 mL).	
Refluxed	for	1	h	on	oil	bath	to	give	the	different	derivatives	of	
1,3,4‐thiadiazole	at	the	C2	positions	respectively.		
2‐(5‐((2,4,5‐trichlorophenylamino)methyl)‐1,3,4‐thiadiazol‐
2‐ylthio)‐1‐phenyl	ethanone	(5a):	Yield:	62%.	M.p.:	232‐234	oC.	
IR(KBr,	 ν,	 cm‐1):	 3375	 (NH	str.),	 3046	 (CH2),	 1722	 (C=O),	 717	
(Cl	str.).	1H	NMR	(400	MHz,	DMSO‐d6,	δ,	ppm):	8.10	(s,	1H,	Ar‐
H),	7.92	(s,	1H,	Ar‐H),	7.64‐7.62	(d,	 J	=	8.2	Hz,	2H,	Ar‐H),	7.33‐
7.31	(d,	J	=	7.6	Hz,	2H,	Ar‐H),	6.93(s,	1H,	Ar‐H),	4.03	(s,	1H,	NH),	
3.87	 (s,	2H,	 ‐S‐CH2‐CO),	2.50	 (s,	 2H,	CH2).	 13C	NMR	 (100	MHz,	
DMSO‐d6,	 δ,	 ppm):	 193.52	 (C=O),	 160.07	 (C2‐triazolic	 ring),	
157.06	 (C5‐triazolic	 ring),	 142.11,	 140.03,	 131.32,	 130.15,	
124.99,	 121.50,	 119.61,	 112.97	 (Aromatic	 ring),	 49.23	 (CH2),	
39.02	 (‐S‐CH2‐CO).	MS	 (ESI‐QqTOF,	m/z):	 443.99	 [M+1].	 Anal.	
calcd.	 for	 C17H12Cl3N3OS2:	 C,	 45.91;	H,	 2.72;	N,	 9.45.	 Found:	 C,	
45.90;	H,	2.70;	N,	9.42%.	
2‐(5‐((2,4,5‐trifluorophenylamino)methyl)‐1,3,4‐thiadiazol‐
2‐ylthio)‐1‐phenylethanone	 (5b):	Yield:	 51%.	M.p.:	 245‐247	 oC.	
IR(KBr,	ν,	cm‐1):	3348	(NH	str.),	3037	(CH2),	1738	(C=O),	714	(F	
str.).	 1H	NMR	(400	MHz,	DMSO‐d6,	δ,	ppm):	7.91	(s,	1H,	Ar‐H),	
7.82	(s,	1H,	Ar‐H),	7.57‐7.54	(d,	J	=	8.6	Hz,	2H,	Ar‐H),	7.24‐7.21	
(d,	J	=	8.2	Hz,	2H,	Ar‐H),	7.02	(s,	1H,	Ar‐H),	4.06	(s,	1H,	NH),	3.54	
(s,	2H,	‐S‐CH2‐CO),	2.07	(s,	2H,	CH2).	13C	NMR	(100	MHz,	DMSO‐
d6,	 δ,	 ppm):	 187.33(C=O),	 158.27	 (C2‐triazolic	 ring),	 150.12	
(C5‐triazolic	 ring),	 141.17,	 140.09,	 134.76,	 130.57,	 127.19,	
120.77,	118.78,	112.07	(Aromatic	ring),	50.21	(CH2),	38.22	(‐S‐
CH2‐CO).	MS	 (ESI‐QqTOF,	m/z):	 395.91	 [M+1].	 Anal.	 calcd.	 for	
C17H12F3N3OS2:	C,	 51.64;	H,	 3.06;	N,	10.63.	 Found:	 C,	51.62;	H,	
3.02;	N,	10.62%.	
2‐(5‐((2,4,5‐trichlorophenylamino)methyl)‐1,3,4‐thiadiazol‐
2‐ylthio)‐1‐(4‐chloro	 phenyl)ethanone	 (5c):	 Yield:	 45%.	 M.p.:	
240‐241	oC.	 IR(KBr,	ν,	cm‐1):	3375	(NH	str.),	3048	(CH2),	1723	
(C=O),	725	(Cl	str.).	1H	NMR	(400	MHz,	DMSO‐d6,	δ,	ppm):	8.61	
(s,	1H,	Ar‐H),	8.10	(s,	1H,	Ar‐H),	7.77‐7.75	(d,	J	=	8.0	Hz,	2H,	Ar‐
H),	7.25‐7.24	(d,	J	=	7.6	Hz,	2H,	Ar‐H),	3.99	(s,	1H,	NH),	3.01	(s,	
2H,	‐S‐CH2‐CO),	2.62	(s,	2H,	CH2).	13C	NMR	(100	MHz,	DMSO‐d6,	
δ,	ppm):	194.78	 (C=O),	164.96	 (C2‐triazolic	 ring),	135.75	 (C5‐
triazolic	 ring),	 133.88,	 131.63,130.57,	 130.01,	 129.03,	 127.16,	
114.72,	110.17	(Aromatic	ring),	50.89	(CH2),	38.87	(‐S‐CH2‐CO).	
MS	 (ESI‐QqTOF,	 m/z):	 477.1	 [M+H]+.	 Anal.	 calcd.	 for	
C17H11Cl4N3OS2:	 C,	 42.61;	 H,	 2.31;	 N,	 8.77.	 Found:	 C,	 42.58;	H,	
2.28;	N,	8.75%.	
2‐(5‐((2,4,5‐trifluorophenylamino)methyl)‐1,3,4‐thiadiazol‐
2‐ylthio)‐1‐(4‐chloro	 phenyl)ethanone	 (5d):	 Yield:	 54%.	 M.p.:	
215‐216	oC.	 IR(KBr,	ν,	cm‐1):	3441	(NH	str.),	3377	(CH2),	1715	
(C=O),	730	(F	str.).	1H	NMR	(400	MHz,	DMSO‐d6,	δ,	ppm):	7.83	
(s,	1H,	Ar‐H),	7.67	(s,	1H,	Ar‐H),	7.12‐7.09	(d,	J	=	7.8	Hz,	2H,	Ar‐
H),	6.98‐6.96	(d,	J	=	7.2	Hz,	2H,	Ar‐H),	4.01	(s,	1H,	NH),	3.85	(s,	
2H,	‐S‐CH2‐CO),	2.46	(s,	2H,	CH2).	13C	NMR	(100	MHz,	DMSO‐d6,	
δ,	ppm):	192.71	 (C=O),	167.69	 (C2‐triazolic	 ring),	136.76	 (C5‐	
triazolic	 ring),	 131.18,	 130.63,130.07,	 129.88,	 129.03,	 126.16;	
115.72,	111.17	(aromatic	ring),	49.89	(CH2),	39.97	(‐S‐CH2‐CO).		
MS	 (ESI‐QqTOF,	 m/z):	 429.1	 [M+H]+.	 Anal.	 calcd.	 for	
C17H11ClF3N3OS2:	C,	47.50;	H,	2.58;	N,	9.78.	Found:	C,	47.48;	H,	
2.57;	N,	9.74%.	
2‐(5‐((2,4,5‐trichlorophenylamino)methyl)‐1,3,4‐thiadiazol‐
2‐ylthio)‐1‐(4‐fluoro	 phenyl)ethanone	 (5e):	 Yield:	 58%.	 M.p.:	
212‐215	oC.	 IR(KBr,	ν,	cm‐1):	3375	(NH	str.),	3046	(CH2),	1722	
(C=O),	717	(Cl	str.).	1H	NMR	(400	MHz,	DMSO‐d6,	δ,	ppm):	8.12	
(s,	1H,	Ar‐H),	7.92	(s,	1H,	Ar‐H),	7.35‐7.32	(d,	J	=	8.6	Hz,	2H,	Ar‐
H),	7.05‐7.02	(d,	J	=	7.4	Hz,	2H,	Ar‐H),		4.07	(s,	1H,	NH),	3.81	(s,	
2H,	‐S‐CH2‐CO),	2.42	(s,	2H,	CH2).	13C	NMR	(100	MHz,	DMSO‐d6,	
δ,	ppm):	193.20	 (C=O),	162.50	 (C2‐triazolic	 ring),	152.72	 (C5‐
triazolic	 ring),	141.30,	139.89,	134.38,	132.37,	130.06,	129.09,	
127.88,	127.33,	126.61	(Aromatic	ring),	49.27	(CH2),	39.63	(‐S‐
CH2‐CO).	MS	(ESI‐QqTOF,	m/z):		461.09	[M+H]+.	Anal.	calcd.	for	
C17H11Cl3FN3OS2:	C,	44.12;	H,	2.40;	N,	9.08.	Found:	C,	44.09;	H,	
2.44;	N,	9.04%.	
2‐(5‐((2,4,5‐trifluorophenylamino)methyl)‐1,3,4‐thiadiazol‐
2‐ylthio)‐1‐(4‐fluoro	 phenyl)ethanone	 (5f):	 Yield:	 54%.	 M.p.:	
240‐241	oC.	 IR(KBr,	ν,	cm‐1):	3348	(NH	str.),	3037	(CH2),	1738	
(C=O),	717	(F	str.).	1H	NMR	(400	MHz,	DMSO‐d6,	δ,	ppm):	8.12	
(s,	1H,	Ar‐H),	7.83	(s,	1H,	Ar‐H),	7.52	‐7.50	(d,	J	=	8.6	Hz,	2H,	Ar‐
H),	6.60‐6.58	(d,	J	=	6.6.Hz,	2H,	Ar‐H),	4.09	(s,	1H,	NH),	3.83	(s,	
2H,	‐S‐CH2‐CO),	2.52	(s,	2H,	CH2).	13C	NMR	(100	MHz,	DMSO‐d6,	
δ,	 ppm):	 193.1	 (C=O),	 162.77	 (C2‐triazolic	 ring),	 152.10	 (C5‐
triazolic	 ring),	142.90,	140.71,	133.68,	130.91,	130.20,	127.60,	
123.9,	 123.7,	 115.18	 (Aromatic	 ring),	 49.21	 (CH2),	 39.17	 (‐S‐
CH2‐CO).	MS	(ESI‐QqTOF,	m/z):	413.90	[M+H]+.	Anal.	calcd.	for	
C17H11F4N3OS2:	C,	 49.39;	H,	2.68;	N,	10.16.	Found:	C,	49.35;	H,	
2.65;	N,	10.14%.	
	
2.3.	Biological	evaluation	
	
2.3.1.	In	vitro	evaluation	of	antimicrobial	activity	
	
The	 MIC	 determination	 of	 the	 tested	 compounds	 were	
carried	 out	 in	 side‐by‐side	 comparison	 with	 Norfloxacin	 for	
their	antibacterial	activity	against	 two	micro‐organisms	viz.	E.	
coli	 (NCTC	 10418)	 and	 S.	 aureus	 (NCTC	 6571)	 by	 Cup‐plate	
agar	 diffusion	 method	 using	 Mueller‐Hinton	 agar.	 The	 MIC	
determinations	 of	 the	 tested	 compounds	were	 carried	 out	 by	
comparison	 with	 Griseofulvin	 for	 their	 antifungal	 activity	
against	C.	albicans	(ATCC	10231)	and	A.	niger	(ATCC	16404)	by	
Cup‐plate	 agar	 diffusion	 method	 using	 Sabouraud‐Dextrose	
agar.	 Drugs	 (10mg)	 were	 dissolved	 in	 Dimethylsulfoxide	
(DMSO,	 1	 mL).	 The	 tubes	 were	 inoculated	 with	 105	 cfu/mL	
(colony	forming	unit/mL)	and	incubated	at	37	oC	for	18	h.	The	
MIC	was	the	lowest	concentration	of	the	tested	compound	that	
yields	no	visible	growth	on	the	plate.	To	ensure	that	the	solvent	
had	no	effect	on	the	bacterial	growth,	a	control	was	performed	
with	 DMSO	 at	 the	 same	 dilutions	 as	 used	 in	 the	 experiments	
and	 it	was	observed	 that	DMSO	with	2%	had	no	effect	on	 the	
microorganisms	in	the	concentrations	studied.		
	
2.3.2.	In	vitro	evaluation	of	antitubercular	activity	
	
The	antimycobacterial	activity	of	compounds	was	assessed	
against	 M.	 tuberculosis	 using	 microplate	 Alamar	 Blue	 assay	
(MABA).	The	96	wells	plate	received	100	µL	of	the	Middlebrook	
7H9	broth	and	serial	dilution	of	compounds	was	made	directly	
on	plate.	The	final	drug	concentrations	tested	were	100	to	0.2	
µg/mL	and	incubated	at	37	oC	for	five	days.	After	this	25	µL	of	
freshly	prepared	 1:1	mixture	 of	 Almar	Blue	 reagent	 and	 10%	
tween	80	was	 added	 to	 the	plate	 and	 incubated	 for	 24	hrs.	A	
blue	color	 in	 the	well	was	 interpreted	as	no	bacterial	 growth,	
and	pink	color	was	scored	as	growth.	The	MIC	was	defined	as	
lowest	 drug	 concentration,	which	 prevented	 the	 color	 change	
from	blue	to	pink.	Against	the	standard	drug	Isoniazid.		
	
2.3.3.	Experimental	protocol	of	molecular	docking	studies	
	
The	 synthesized	 molecules	 were	 subjected	 for	 molecular	
docking	by	calculating	the	minimum	energy	to	inhibit	the	target	
protein	 involved	 in	 the	 catalysis	 of	 complex	 reaction.	 The	
ligands	 were	 drawn	 in	 Chemdraw	 Ultra	 11.0	 assigned	 with	
proper	2D	orientation	(Chemoffice	package)	and	the	structure	
of	 each	 ligand	 was	 analysed	 by	 using	 Chem‐3D	 Ultra	 11.0	
(ChemOffice	 package)	 and	 was	 checked	 for	 the	 connection	
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error	 in	 bond	 order.	 ADMET	 property	 was	 achieved	 through	
PreADMET	 server	 a	 web‐based	 application	 for	 predicting	
ADMET	 data	 and	 building	 drug‐like	 library	 using	 in	 silico	
method.	 Energy	 of	 the	 molecules	 was	 minimized	 by	 using	
MOPAC	with	100	interactions	and	minimum	RMS.	Then	the	file	
was	 opened	 in	 Accelrys,	 DS	 visualizer	 2.0	 [Accelrys	 Inc.,	 San	
Diego,	CA	(2007)]	and	to	determine	their	binding	orientations,	
molecular	 modeling,	 and	 evaluation	 of	 the	 hydrogen	 bonds.	
Active	pockets	were	identified	and	ligplot	of	PDBSum	provided	
in	 the	External	 links	of	PDB	 for	 the	proteins	was	downloaded	
from	 PDB.	 CASTp	 (Computed	 Atlas	 of	 Surface	 Topography	 of	
proteins)	server	was	used	to	crosscheck	the	active	pockets	on	
target	 protein	molecules.	Autodock	V4.0	was	used	 to	perform	
molecular	 docking.	 The	 docking	 results	 for	 ligand	 molecules	
against	 ecKAS	 III	 synthase	 [PDB	 ID:	 1hnj],	 showed	minimum	
docking	 energy,	 binding	 energy,	 number	of	binding	 sites	with	
0.0	RMS	as	documented	in	Table	1.	
	
Table	1.	Molecular	docking	simulation	results	with	ecKAS	III	synthase.	
Molecule	no	 Binding	energy	 Docking	energy	 No	of	binding	sites	
5a	 ‐5.49	 ‐5.70	 4	
5b	 ‐6.79	 ‐6.92	 3	
5c	 ‐5.79	 ‐5.92	 2	
5d	 ‐6.53	 ‐6.81	 4	
5e	 ‐6.99	 ‐7.22	 3	
5f	 ‐5.19	 ‐5.24	 2	
	
3.	Result	and	discussion	
	
The	synthetic	route	of	the	compounds	(5a‐f)	is	outlined	in	
Scheme	1.		The	2‐(substituted	phenylamino)acetic	acid	(1)	was	
prepared	 by	 the	 reaction	 of	 equimolar	 quantities	 of	
chloroacetic	 acid	 and	 substituted	 aniline	 according	 to	 the	
established	procedures	[13].	Ethyl‐2‐(substitutedphenylamino)	
acetate	 (2)	 was	 obtained	 by	 refluxing	 2‐(susbtituted	
phenylamino)acetic	acid	(1)	and	Concentrated	sulphuric	acid	in	
presence	 of	 dry	 ethanol	 to	 form	 esters	 [14].	 2‐(substituted	
phenylamino)acetohydrazide	 (3)	 was	 prepared	 by	
hydrozinolysis	 of	 the	 esters.	 Synthesis	 of	 5‐((substituted	
phenylamino)methyl)‐1,3,4‐thiadiazole‐2‐thiol	 (4)	 was	
achieved	by	adopting	a	simple	one	pot	procedure	that	involves	
reacting	 hydazides	 with	 carbon	 disulfide	 and	 conc.	 sulphuric	
acid	 [15].	 The	 alkylation	 of	 1,3,4‐thiadiazoles	 (4)	 with	
substituted	 phenycyl	 bromide,	 in	 presence	 of	 dimethyl	
sulfoxide	afford	a	new	series	of	1‐(2,4,5‐trisubstitutedphenyl)‐
2‐(5‐((substitutedphenylamino)methyl)‐1,3,4‐thiadiazol‐2‐
ylthio)ethanone	(5a‐f)	[16].	
The	formation	of	2‐substituted	phenylamino	acetic	acid	(1)	
was	 confirmed	 by	 IR	 spectra,	 which	 showed	 the	 presence	 of	
amine(‐NH)	 bands	 at	 around	3415	 to	 3375	 cm‐1	 and	 1H	NMR	
D2O	 exchange	 experiment	 around	 4.08	 ppm.	 Ethyl‐2‐
(substitutedphenylamino)acetate	 (2)	 showed	 around	 1722	 to	
1698	 cm‐1	 (C=O).	 2‐(Substituted	 phenylamino)acetohydrazide	
(3)	was	confirmed	by	3450	 to	3398	cm‐1	(NH2)	and	 the	signal	
was	observed	around	8.22	ppm	in	the	1H	NMR.	A	new	signal	for	
SH	group	was	appeared	as	singlet	at	δ	12.87‐12.78	ppm.	In	the	
1H	 NMR	 spectra	 of	 1‐(2,4,5‐trisubstitutedphenyl)‐2‐(5‐
((substitutedphenylamino)methyl)‐1,3,4‐thiadiazol‐ylthio)	
ethanone	(5a‐f)	were	confirmed	by	absence	of	SH	peak,		while	
the	 signal	 of	 methylene	 proton	 (2.62‐2.07	 ppm)	 from	
compounds	 were	 appeared.	 The	 above	 facts	 were	 further	
evidenced	 by	 13C	 NMR	 data	 which	 displayed	 C=O	 signals	 at	
194.78‐187.77	 ppm,	 the	 heterocyclic	 carbons	 resonated	 at	
167.69	 to	 110.17	 ppm	 and	 CH2	 group	 resonated	 at	 39.97	 to	
38.22	 ppm	 respectively.	 The	 mass	 spectrum	 of	 compounds	
showed	 molecular	 ion	 peaks	 at	 m/z	 475.1	 to	 395.0	
corresponding	to	molecular	 formula	and	elemental	analysis	of	
these	compounds	further	confirmed	the	assigned	structures.		
	
3.1.	Biological	evaluation	
	
3.1.1.	In	vitro	antimicrobial	studies	
The	 investigation	 of	 antimicrobial	 screening	 revealed	 that	
some	 of	 compounds	 showed	moderate	 to	 good	 bacterial	 and	
fungal	 inhibition.	 Particularly	 compounds	 5a	 and	 5d	 showed	
good	 activity	 against	 E.	 Coli	 and	 S.	 aureus	 with	 MIC	 values	
between	8	 to	16	µg/mL.	All	 the	 remaining	 compounds	5b,	5e	
and	 5f	 showed	 moderate	 activity,	 where	 as	 5c	 shown	 less	
activity.	The	investigation	of	antifungal	screening	revealed	that	
compounds	5a	 and	5e	 showed	 good	 activity	 against	A.	Niger	
and	C.	Albicans	with	MIC	values	between	8	to	16	µg/mL.	All	the	
remaining	compounds	5b,	5c	and	5f	showed	moderate	activity,	
where	 as	 5d	 shown	 less	 activity.	 The	 MIC	 values	 of	 tested	
compounds	are	given	in	Table	2	[17].		
	
Table	2.	 Antimicrobial	 and	 anti‐tubercular	 screening	 results	 of	 compound	
(MIC	values	µg/mL).	
Compounds	
Anti‐microbial		
activity	
Anti‐tubercular	
activity	
E.		
Coli	
S.	
Aureus	
A.	
Niger	
C.	
Albicans	
M.	tubercular	
H37Rv	
5a 16 8 16 8	 0.8	
5b 31.25 62.50 31.25 125	 3.125	
5c 125 500 62.5 250	 25	
5d 16 8 16 125	 0.8	
5e	 62.5	 31.25	 8	 16	 6.25	
5f	 16	 125	 16	 125	 3.125	
Norfloxacin	 <1	 <5	 NT	 NT	 NT	
Griseofulvin	 NT	 NT	 <1	 <5	 NT	
Isoniazid NT NT NT NT	 <0.2	
NT:	not	tested.	
	
3.1.2.	In	vitro	antitubercular	studies	
	
The	 antitubercular	 screening	 revealed	 that	 some	 of	 the	
tested	compounds	showed	moderate	to	good	inhibition	against	
standard	 drug	 Isoniazid.	 Particularly	 compounds	 5a	 and	 5d,	
have	shown	good	activity	with	MIC	values	between	0.4	 to	1.6	
µg/mL.	 All	 the	 remaining	 compounds	 5b,	 5e	 and	 5f	 showed	
moderate	activity,	where	as	5c	has	shown	less	activity	[18].	
	
3.1.3.	Molecular	docking	studies	
	
With	 in	 vitro	 antimicrobial	 results	 in	 hand,	 it	 is	 thought	
worth‐while	 to	 do	 in	 silico	 studies	 to	 support	 the	 in	 vitro	
activity.	 Automated	 docking	 was	 used	 to	 determine	 the	
orientation	 of	 inhibitors	 bound	 in	 the	 active	 site	 of	 ecKAS	 III	
synthase.	 A	 Lamarckian	 genetic	 algorithm	 method	 was	
employed.	 The	 docking	 of	 ligand	 molecules	 with	 ecKAS	 III	
synthase	reveals	that	all	the	inhibitor	compounds	are	exhibited	
the	 bonding	 with	 one	 or	 other	 amino	 acids	 in	 the	 active	
pockets,	which	is	showed	in	Figure	1.	The	protein	structure	file	
(PDB	ID:	1hnj)	taken	from	PDB	(www.rcsb.org/pdb)	was	edited	
by	 removing	 the	 hetero	 atoms,	 adding	 C‐terminal	 oxygen.		
Figure	 1	 also	 shows	 the	 in	 silico	 active	 pocket	 prediction	 of	
amino	acids	of	protein	ecKAS	 III	 synthase	 involved	 in	binding	
with	 the	 ligands	obtained	 from	PDB	sum.	Theoretically	all	 the	
molecules	 showed	 very	 good	 binding	 energy	 and	 docking	
energy	 ranging	 from	 ‐5.19	 to	 ‐6.99	 kJ/mol	 and	 ‐5.24	 to	 ‐7.22	
kJ/mol,	respectively.	Among	the	6	molecules,	docking	of	ecKAS	
III	 synthase	 with	 5b	 and	5f	 revealed	 that	 its	 docking	 energy	
and	binding	energy	were	 ‐6.79,	 ‐6.92,	 ‐6.99,	 and	 ‐7.22	kJ/mol,	
respectively,	 and	 it	 may	 be	 considered	 as	 good	 inhibitor	 of	
ecKAS	 III	 synthase.	 In	 in‐vitro	also	5b	and	5f	 has	 emerged	 as	
active	against	all	tested	microorganisms,	so	it	can	be	predicted	
as	 the	 activity	 may	 be	 due	 to	 inhibition	 of	 enzyme	 ecKAS	 III	
synthase	[19,20].	
	
4.	Conclusion	
	
We	 have	 synthesized	 series	 of	 novel	 S‐substituted	
phenacyl‐1,3,4‐thiadiazole‐thiol	 derivatives	 (5a‐f).	 The	 results	
of	 antimicrobial	 screening	 revealed	 the	 discovery	 of	 new	
compounds,	which	could	be	promising	agents.	This	observation	
may	 promote	 a	 further	 development	 of	 this	 group	 of	 1,3,4‐
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thiadiazole‐thiol	 that	 may	 lead	 to	 compounds	 with	 better	
pharmacological	 profile	 than	 standard	 antimicrobial	 drugs.	
Molecular	 docking	 studies	 also	 revealed	 that	 5b	 and	 5f	 has	
minimum	binding	and	docking	energy	and	may	be	considered	
as	a	good	inhibitor	of	ecKAS	III.	Hence	this	study	has	widened	
the	 scope	 of	 developing	 these	 derivatives	 as	 promising	
antitubercular,	antibacterial	and	antifungal	agents.	
	
	
		
		
				
	
Figure	 1.	 Compound	 1b	 is	 bound	 into	 ecKAS	 III	 receptor	 site	 via	
hydrophobic	 interactions	 and	 hydrophilic	 binding	 by	 hydrogen	 bond	
between	its	O	and	H‐S	of	Asn	274	(S‐H…02:	2.03	Å,	137.8	 o)	and	H‐S	of	Ala	
109	(S‐H…02:	2.08	Å,	148.7	o)	and	extending	into	the	mouth	of	the	substrate	
tunnel	(2d	(ii)).	
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